Atherosclerotic Cardiovascular Disease Epidemiology, Pathophysiology, and Practical Risk Assessment

被引:0
|
作者
Derr, Jerica N. [1 ,2 ]
Black, Ashley [3 ,4 ]
机构
[1] Oregon Hlth & Sci Univ, Dept Phys Assistant Educ, Div Educ, 2730 South Moody Ave, CL5PA, PORTLAND, OR 97201 USA
[2] Still Univ DMSc Program, Dept Phys Assistant Studies, Mesa, AZ USA
[3] Charleston Southern Univ, Coll Hlth Sci, Phys Assistant Studies Program, Hlth Sci Bldg,9200 Univ Blvd, Charleston, SC 29406 USA
[4] 117 Moon Shadow Lane, Summerville, SC 29485 USA
关键词
Atherosclerosis; ASCVD; Cardiovascular risk; Endothelial dysfunction; Plaque formation; Lifestyle modification; Risk assessment tools; HEART-DISEASE; MECHANISMS; GUIDELINE; ACC/AHA; THERAPY; US;
D O I
10.1016/j.cpha.2024.11.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In summary, ASCVD is a chronic condition driven by endothelial dysfunction and lipid accumulation, leading to plaque development and potential cardiovascular events. This article discusses key risk factors, including hypercholesterolemia, HTN, smoking, diabetes, and age, which collectively contribute to ASCVD progression. Understanding the pathophysiology of plaque formation-beginning with endothelial dysfunction and advancing to plaque rupture-is critical for clinical management. The use of risk assessment tools, such as the Framingham Risk Score and ACC/AHA Risk Estimator, provides clinicians with methods to evaluate and manage patient risk. This personalized approach can guide lifestyle and pharmacologic interventions that effectively mitigate ASCVD-related morbidity and mortality.
引用
收藏
页码:189 / 199
页数:11
相关论文
共 50 条
  • [31] Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease
    Jaiswal, S.
    Natarajan, P.
    Silver, A. J.
    Gibson, C. J.
    Bick, A. G.
    Shvartz, E.
    McConkey, M.
    Gupta, N.
    Gabriel, S.
    Ardissino, D.
    Baber, U.
    Mehran, R.
    Fuster, V.
    Danesh, J.
    Frossard, P.
    Saleheen, D.
    Melander, O.
    Sukhova, G. K.
    Neuberg, D.
    Libby, P.
    Kathiresan, S.
    Ebert, B. L.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (02): : 111 - 121
  • [32] Estimation of Atherosclerotic Cardiovascular Disease Risk in Veterans
    Djousse, Luc
    Vassy, Jason L.
    Gagnon, David R.
    Lu, Bing
    Ho, Yuk-Lam
    Costa, Lauren
    Gaziano, J. M.
    Cho, Kelly
    Wilson, Peter W.
    CIRCULATION, 2019, 139
  • [33] Remnant Cholesterol and Atherosclerotic Cardiovascular Disease Risk
    Burnett, John R.
    Hooper, Amanda J.
    Hegele, Robert A.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 76 (23) : 2736 - 2739
  • [34] Triglycerides as Residual Risk for Atherosclerotic Cardiovascular Disease
    Ohmura, Hirotoshi
    CIRCULATION JOURNAL, 2019, 83 (05) : 969 - 970
  • [35] Inflammatory biomarkers and risk of atherosclerotic cardiovascular disease
    Yu, En
    Hsu, Hsin-Yin
    Huang, Chun-Yuan
    Hwang, Lee-Ching
    OPEN MEDICINE, 2018, 13 (01): : 208 - 213
  • [36] Epidemiology of risk factors for cardiovascular disease
    Yahia-Berrouiguet, A.
    Meguenni, K.
    Brouri, M.
    DIABETES & METABOLISM, 2012, 38 : A114 - A114
  • [37] Eliminating atherosclerotic cardiovascular disease residual risk
    Makover, Michael E.
    Surma, Stanislaw
    Banach, Maciej
    Toth, Peter P.
    EUROPEAN HEART JOURNAL, 2023, 44 (45) : 4731 - 4733
  • [38] Multifocal atherosclerotic disease and the risk for cardiovascular events
    Poredos, P.
    Bregar, U.
    Poredos, P., Jr.
    Visnovic-Poredos, A.
    EUROCHAP: Proceedings of the 16th European Chapter Congress of the International Union of Angiology, 2005, : 31 - 35
  • [39] Antiphospholipid Antibodies and Risk of Atherosclerotic Cardiovascular Disease
    Nogueira, Alleh
    Tramujas, Lucas
    Felix, Nicole
    Costa, Thomaz
    Carvalho, Pedro
    CIRCULATION, 2024, 150
  • [40] Highlighting Residual Atherosclerotic Cardiovascular Disease Risk
    Matsuura, Yunosuke
    Kanter, Jenny E.
    Bornfeldt, Karin E.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2019, 39 (01) : E1 - E9